| Identification | Back Directory | [Name]
BCTC | [CAS]
393514-24-4 | [Synonyms]
BCTC
N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)piperazine-1-carboxamide
4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide
1-Piperazinecarboxamide, 4-(3-chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-
4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-diMethylethyl)phenyl]-1-piperazinecarboxaMide (BCTC) | [Molecular Formula]
C20H25ClN4O | [MDL Number]
MFCD08690556 | [MOL File]
393514-24-4.mol | [Molecular Weight]
372.89 |
| Chemical Properties | Back Directory | [Melting point ]
150-152℃ | [Boiling point ]
561.6±50.0 °C(Predicted) | [density ]
1.229±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Room Temperature | [solubility ]
DMSO: >10mg/mL | [form ]
powder | [pka]
13.95±0.70(Predicted) | [color ]
white to beige | [Sensitive ]
Light Sensitive | [Stability:]
Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stord at -20°C for up to 2 months. | [InChIKey]
ROGUAPYLUCHQGK-UHFFFAOYSA-N |
| Hazard Information | Back Directory | [Description]
BCTC (393514-24-4) is a vanilloid receptor I (TRPV1) blocker, IC50 = 35 nM for capsaicin-induced and 6 nM for acid-induced TRPV1 activation. Displays analgesic activity in rat models of neuropathic pain. BCTC is orally active and cell permeable. | [Uses]
BCTC is a antagonists of TRPA1 and TRPV1, a non-selective cation channel gated by noxious heat, vanilloids and extracellular protons. BCTC inhibits both capsaicin and proton activation. | [Definition]
ChEBI: 1-piperazinecarboxamide, 4-(3-chloro-2-pyridinyl)-n-[4-(1,1-dimethylethyl)phenyl]- is a member of piperazines and a member of pyridines. | [storage]
Store at RT | [References]
1) Valenzano et al. (2003), N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties; J. Pharmacol. Exp. Ther., 306 377
2) Pomonis et al. (2003), N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain; J. Pharmacol. Exp. Ther., 306 387 |
|
|